Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 19/20 | 0.56 |
| ▸ | MMP13 | P45452 | 19/20 | 0.56 |
| ▸ | MMP2 | P08253 | 2/20 | 0.56 |
| ▸ | MMP3 | P08254 | 2/20 | 0.56 |
| ▸ | MMP9 | P14780 | 2/20 | 0.56 |
| ▸ | MMP8 | P22894 | 2/20 | 0.56 |
| ▸ | MMP12 | P39900 | 1/20 | 0.49 |
| ▸ | MMP14 | P50281 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25832 | 0.92 | MMP1 (0.57) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL4575861 | 0.87 | MMP1 (0.42) | MMP1MMP13MMP2MMP3MMP9 | |
| Hydroxyamine SCHEMBL19181460 | 0.80 | MMP1 (0.77) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7004525 | 0.80 | MMP1 (0.80) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL4048453 | 0.80 | MMP1 (0.80) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7991333 | 0.80 | MMP2 (0.40) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL6869740 | 0.77 | MMP1 (0.77) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL27415619 | 0.77 | MMP1 (0.76) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7886290 | 0.75 | MMP1 (0.62) | MMP1MMP13MMP2MMP3MMP9 | |
| Hydroxyamine SCHEMBL5914587 | 0.75 | MMP1 (0.76) | MMP1MMP13MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 632 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037404-B2 | Human monoclonal antibodies against EphA4 and their use | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2024-07-16 | — | — | US | disclosed |
| EP-2534153-B2 | SALTS AND POLYMORPHS OF 8-FLUORO-2-{4-[(METHYLAMINO}METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD]INDOL-6-ONE | PFIZER (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240109862-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2024-04-04 | — | — | US | disclosed |
| US-20240083855-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-03-14 | — | — | US | disclosed |
| EP-3590932-B1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY INC (US) | 2023-05-03 | — | — | EP | disclosed |
| EP-4166558-A1 | SALTS AND POLYMORPHS OF 8-FLUORO-2-{4- [(METHYLAMINO)METHYL]PHENYL}-1 ,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3- CD]INDOL-6-ONE | Pfizer Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| EP-3473271-B1 | HUMAN MONOCLONAL ANTIBODIES AGAINST EPHA4 AND THEIR USE | US GOV HEALTH & HUMAN SERVICES (US) | 2022-07-20 | — | — | EP | disclosed |
| US-20220162200-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. | 2022-05-26 | — | — | US | disclosed |
| US-11124499-B2 | Pharmaceutical composition derived from Tecoma plant and a method for treating cancer | NATIONAL GUARD HEALTH AFFAIRS (SA) | 2021-09-21 | — | — | US | disclosed |
| US-20210277037-A1 | DEUTERATED ALVOCIDIB AND ALVOCIDIB PRODRUGS | SUMITOMO PHARMA ONCOLOGY, INC. | 2021-09-09 | — | — | US | disclosed |
| EP-1177791-A2 | Use of glycogen phosphorylase inhibitors to inhibit tumor growth | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
| US-20020004511-A1 | Thiophene derivatives useful as anticancer agents | LUZZIO MICHAEL JOSEPH (US) | 2002-01-10 | — | — | US | disclosed |
| WO-2001098277-A2 | SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001094353-A1 | THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2001-12-13 | — | — | WO | disclosed |
| EP-1150973-A1 | HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2001053289-A1 | ANTICANCER COMPOUND AND ENANTIOMER SEPARATION METHOD USEFUL FOR SYNTHESIZING SAID COMPOUND | PFIZER PRODUCTS INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| US-6258824-B1 | TREATMENT OF HYPERPROLIFERATIVE DISEASES, SUCH AS CANCERS, IN MAMMALS. THIS INVENTION ALSO RELATES TO A PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS. | PFIZER INC. | 2001-07-10 | — | — | US | disclosed |
| EP-1106612-A1 | Quinoline derivatives useful for inhibiting farnesyl protein transferase | Pfizer Products Inc. (US) | 2001-06-13 | — | — | EP | disclosed |
| WO-2001040217-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| WO-2000047574-A1 | HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004511-A1 | Thiophene derivatives useful as anticancer agents | CCNA1, CCNE1, TP53 | MMP1 2429/4885MMP13 4017/4885MMP2 4517/4885 |
| US-20220162200-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PKM, PDK2 | MMP1 4359/4885MMP13 3911/4885MMP2 3348/4885 |
| US-20240083855-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | ALK, JAK2, JAK1 | MMP1 2298/4885MMP13 2440/4885MMP2 2512/4885 |
| US-20210277037-A1 | DEUTERATED ALVOCIDIB AND ALVOCIDIB PRODRUGS | CDK4, CDK11B, CDK3 | MMP1 1315/4885MMP13 820/4885MMP2 1970/4885 |
| US-20240109862-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | MMP1 3955/4885MMP13 4604/4885MMP2 4086/4885 |
| US-11124499-B2 | Pharmaceutical composition derived from Tecoma plant and a method for treating cancer | TEC, TMSB10, MALT1 | MMP1 3159/4885MMP13 931/4885MMP2 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.